Search | Clinical Trials Finder

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions: Biopsy of Breast, Biospecimen Collection, Breast Surgery, Chemotherapy, Computed Tomography, Contrast Enhanced Digital Mammography, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Survey Administration, Tissue Collection, Ultrasound Imaging; Procedure · Drug · Radiation + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Alzheimer's Disease
Interventions: MRI, MR Spectroscopy, MR Perfusion; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 45 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Overweight, Obesity, Weight Loss Maintenance
Interventions: Behavior Therapy, Meal Replacements, Nutritrol; Behavioral · Dietary Supplement
Lead sponsor: Drexel University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Atherosclerosis
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 20 Years and older
Enrollment: 886 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Lymphoblastic Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Multigated Acquisition Scan, Positron Emission Tomography, Transplant Conditioning, X-Ray Imaging; Procedure · Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Low Back Pain
Interventions: Fusion or TDR determined by investigator.; Procedure
Lead sponsor: Aclarion; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 7 more

Conditions: GBM, Glioma Glioblastoma Multiforme, Tumor, Brain
Interventions: Whole Brain Spectroscopy Imaging Array Mapping Layout; Diagnostic Test
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 22 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Pemetrexed, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1081
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 694 more

Conditions: Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor
Interventions: Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Triapine; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 11
States / cities: Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 8 more

Conditions: Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions: Biospecimen Collection, Dendritic Cell Therapy, Leukapheresis, Magnetic Resonance Imaging, Poly ICLC; Procedure · Biological · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Endothelial Dysfunction, Albuminuria
Interventions: eplerenone, Hydrochlorothiazide; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 64 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer, Adenocarcinoma of the Prostate Stage I, Adenocarcinoma of the Prostate Stage II, Adenocarcinoma of the Prostate Stage III
Interventions: Magnetic Resonance Imaging; Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Crohn Disease
Interventions: CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Prednisone/Methylprenisolone, Palifermin, ATG, Clofarabine, Melphalan, Total Body Irradiation, Rituximab; Device · Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 30 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: AADC Deficiency
Interventions: AAV2-hAADC; Drug
Lead sponsor: Krzysztof Bankiewicz; Other
Eligibility: 24 Months and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2037
U.S. locations: 3
States / cities: San Francisco, California • Columbus, Ohio

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Electronic Health Record Review, Epcoritamab, Magnetic Resonance Imaging, Obinutuzumab, Venetoclax; Procedure · Other · Biological + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Duarte, California • Irvine, California • Long Beach, California + 4 more

Conditions: Liver Diseases
Interventions: Magnetic Resonance Elastography; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Anti-CFH Monoclonal Antibody GT103, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Pembrolizumab; Biological · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Rhabdomyosarcoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Lumbar Puncture, Lymph Node Biopsy, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Resection, Survey Administration, Vincristine Sulfate, Vinorelbine Tartrate; Procedure · Drug · Biological + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 50 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 86
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 71 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Dual-Energy Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Congenital Heart Disease, Pulmonary Hypertension
Interventions: Magnetic Resonance Imaging; Other
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Veliparib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 9
States / cities: Chicago, Illinois • Harvey, Illinois • Ann Arbor, Michigan + 6 more

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Erdafitinib, Magnetic Resonance Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Safety
Interventions: Ascorbate-Meglumine; Drug
Lead sponsor: LadeRx LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions: MRI-guided Intensity-Modulated Radiation Therapy, Antiandrogen Therapy, PSMA PET Scan, Computed Tomography, Magnetic Resonance Imaging, Bone Scan, Biospecimen Collection, Quality-of-Life Assessment; Procedure · Drug · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Statins in Cerebral Blood Flow and Neuronal Activity--A Pilot Study

A Test of Nutritional Interventions to Enhance Weight Loss Maintenance

Non-Invasive Imaging of Atherosclerosis

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

Examination of Nociscan Impact on Low Back Pain Surgical Outcomes

WBSI Guided Personalized Delivery of TTFields

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma

Aldosterone and Vascular Disease in Diabetes Mellitus

Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

Comparison of MR Elastography Methods Without and With Compressed Sensing

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

MRI and Computational Simulation Cardiology Study

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

Evaluation of Ascorbate-Meglumine Therapeutic for SRS

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer